AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04082195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fooya mobile game
Description: An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
Study NCT04082195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uno board game
Description: A popular board game which is not a mobile app.
Study NCT02123485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency (1 hz) rTMS, as add-on to ECT
Description: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
Study NCT02123485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-rTMS
Description: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
Study NCT02560610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC000459
Study NCT02560610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01843218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of erectile dysfunction
Description: Register R / P and self-administered questionnaire IIEF-5
Study NCT03224897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal tDCS
Description: Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system.
Study NCT03224897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: 1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system.
Study NCT03224897 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups.
Study NCT03238820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic gastric gastrointestinal stromal tumors resection
Description: Robotic gastric gastrointestinal stromal tumors resection
Study NCT06437873 — intervention group
Intervention type: PROCEDURE
Intervention: Total Thyroidectomy (TT)
Description: TT:Surgical removal of the entire thyroid gland.
Study NCT06437873 — intervention group
Intervention type: RADIATION
Intervention: Radioactive iodine treatment(RAIT)
Description: RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
Study NCT03961282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doorway Width Test
Description: The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
Study NCT03961282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Door Frame Color Test
Description: The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
Study NCT03747146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Catheter (ACC)
Description: At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
Study NCT03747146 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Adductor Canal block with sham catheter
Description: Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
Study NCT04077905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 35mg/m² ivgtt on day 1
Study NCT04077905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m² ivgtt on day 1
Study NCT04077905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
Study NCT03243994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Absorption test with D-xylose and zink
Description: Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
Study NCT03017560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive treatment
Description: Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
Study NCT00985205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Glutamine
Description: 0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
Study NCT00985205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
Study NCT00883246 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SilverHawk & TurboHawk Peripheral Plaque Excision System
Description: Removal of atherosclerotic plaque from artery walls.
Study NCT01347034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (RT)
Description: Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival.
Study NCT01347034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy (RT)
Description: Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival.
Study NCT01347034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells
Description: Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities.
Study NCT03612687 — intervention group
Intervention type: DEVICE
Intervention: Minimally invasive hemodynamic monitoring
Description: Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
Study NCT03563937 — intervention group
Intervention type: DRUG
Intervention: Phenprocoumon
Description: Follow the physician's prescription.
Study NCT03563937 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: 2.5 mg or 5 mg, twice daily
Study NCT03563937 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg or 20 mg, once daily
Study NCT03563937 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: 30 mg or 60 mg, once daily
Study NCT01847885 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Smartpatch Peripheral Nerve Stimulation (PNS) System
Description: The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
Study NCT01847885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpatch Peripheral Nerve Stimulation (PNS) System
Description: The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).
Study NCT02618447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4Dimensional Phase Contrast Magnetic Resonance Angiography
Description: 4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
Study NCT02618447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein embolization
Study NCT03877172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
Study NCT00743379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
Study NCT03368183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care delivery algorithim
Description: SCAMP
Study NCT03368183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care delivery algorithim
Description: SCAMP
Study NCT00419328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level
Study NCT03786549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pediatric-adult care transition program
Description: Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients
Study NCT03887299 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)
Description: Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
Study NCT03887299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Wound care will be administered as standard protocol in our institution
Study NCT03513003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Pacifier
Description: Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
Study NCT03513003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop habit
Description: Children stop the use of their pacifier and/or baby bottle
Study NCT02450578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 400mg
Description: DSM265 400mg, single oral administration in a fed state
Study NCT02450578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to DSM265 400 mg
Description: Placebo to DSM265 400mg, single oral administration in a fed state
Study NCT02450578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
Study NCT02450578 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum sporozoite challenge
Description: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
Study NCT02450578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: 250 mg atovaquone, 100 mg proguanil hydrochloride
Study NCT01568606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Composition Analysis InBody Scale
Description: Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist.
Study NCT04016311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Drinking/Eating Intervention
Description: Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
Study NCT00065728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Description: One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
Study NCT02347176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection with placebo
Study NCT02347176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 1
Description: Subcutaneous injection with tralokinumab
Study NCT02347176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 2
Description: Subcutaneous injection with tralokinumab
Study NCT02347176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab Dose 3
Description: Subcutaneous injection with tralokinumab
Study NCT02866825 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IFX-1
Study NCT02866825 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03511131 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Queer Sex Ed
Description: Comprehensive sexual health education program condition (Informational)
Study NCT03511131 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up
Description: Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
Study NCT03511131 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Keep It Up-Control
Description: HIV knowledge control condition, attention-matched to KIU (Informational)
Study NCT03511131 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Young Men's Health Project
Description: Motivational enhancement video interviewing condition (Motivational/behavioral)
Study NCT02613598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02613598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy (injection)
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin chemotherapy (injection)
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin chemotherapy (injection)
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil chemotherapy (injection)
Study NCT04031703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)
Study NCT02026609 — intervention group
Intervention type: OTHER
Intervention: Oral glutamine challenge
Description: Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
Study NCT02026609 — intervention group
Intervention type: OTHER
Intervention: Psychometric Tests
Description: PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
Study NCT03607760 — intervention group
Intervention type: DEVICE
Intervention: ECMO
Description: the patients with severe respiratory failure were supported by ECMO
Study NCT03607760 — intervention group
Intervention type: DEVICE
Intervention: conventional mechanical ventilation
Description: the patients with severe respiratory failure were supported by conventional mechanical ventilation
Study NCT02369276 — intervention group
Intervention type: OTHER
Intervention: ultrasonography and elastography
Description: Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
Study NCT03119519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Definitive Radiotherapy
Description: three-dimensional conformal therapy or intensity modulated radiation therapy
Study NCT03119519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Local Definitive Radiotherapy
Description: Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
Study NCT03119519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Local Definitive Radiotherapy
Description: Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
Study NCT04567212 — intervention group
Intervention type: GENETIC
Intervention: genetic evaluation
Description: A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
Study NCT04567212 — intervention group
Intervention type: OTHER
Intervention: MicroRNA evaluation
Description: Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
Study NCT02914262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-4924
Description: Comparison of different dosages of AKB-4924